Researchers studying blood from football-player brain donors found biomarkers that could identify the most severe cases of chronic traumatic encephalopathy (CTE), Scientific American reports. The small study, published in JAMA on November 19, 2026, points toward a possible way to diagnose a disease that currently can be confirmed only after death. Source
The study involved 21 donors, 18 of whom were found to have CTE after death. Senior author Michael Alosco, co-director of clinical research at Boston University’s CTE Center, cautioned that the test isn’t approved by the U.S. Food and Drug Administration and that more research is needed to confirm the findings. Source
CTE is a neurodegenerative disease linked to repeated head trauma, including collisions in American football. It can cause changes in mood, behavior and memory. Because diagnosis currently requires an autopsy, identifying affected people and studying potential treatments remain difficult. Source
Why Alzheimer’s complicates the test
The approach involves a biomarker called eMTBR-tau. Alosco explained to Scientific American that this biological signal can help detect tangles of tau protein, which misfolds and accumulates in brain cells in CTE and Alzheimer’s disease. Source
Alosco said eMTBR-tau is elevated in both diseases. Finding it doesn’t neatly label a blood sample “CTE.” Source
Another biomarker, p-tau217, tracks closely with Alzheimer’s but not CTE, Alosco said. In theory, testing for both markers could help distinguish the diseases and identify people with CTE. The severe-case findings don’t establish detection across earlier stages of CTE. Source
What a validated test could change
If the findings hold up in larger studies, a future test could help researchers establish how common CTE is in the general population and design better trials of potential treatments, Alosco said. Source
Michael Buckland, a University of Sydney pathology researcher who wasn’t involved in the study, told Scientific American: “While there is still a long way to go before the test can be validated for clinical use, it is remarkable to see how fast the field is moving.” Source
Comments